1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
AssigneeSamumed, LLC
InventorsJohn Hood, Sunil Kumar KC, David Mark Wallace
Life of this patent
Estimating the term…
Abstract
Provided herein are compounds according to Formulas (I) or (II) and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, osteoarthritis, idiopathic pulmonary fibrosis and neurological conditions/disorders/diseases.
Claims30
A compound, or pharmaceutically acceptable salt thereof, having the structure of Formula I:
- wherein:
- R1 is H;
- R2 is independently selected from the group consisting of H and —(C1-9 alkyl)nN(R9)2;
- R3 is H;
- R4 is independently selected from the group consisting of -aryl(R13)q, -furyl(R15)q, and -thiophenyl(R15)q;
- R5 is H;
- each R8 is a substituent attached to the heterocyclyl ring and independently selected from the group consisting of H, halide, and —C1-4 alkyl;
- each R9 is independently selected from the group consisting of H, —C1-9 alkyl, —(C1-3 alkyl)ncarbocyclyl and —(C1-9 alkyl)N(R16)2;
- each R13 is 1-2 substituents each attached to the aryl ring and independently selected from the group consisting of H, halide, —(C1-3 alkyl)nheterocyclyl(R8)q, —(C1-9 alkyl)nN(R9)2 and —(C1-9 alkyl)nNHSO2R18;
- each R15 is a substituent attached to the heteroaryl ring and independently selected from the group consisting of H, lower alkyl, halide, —CF3, CN, and —C(═O)(C1-3 alkyl);
- each R16 is independently selected from the group consisting of H and lower alkyl;
- each R18 is a lower alkyl;
- A is C;
- each q is independently an integer of 1 or 2;
- and
- each n is independently an integer of 0 or 1.
A compound having a structure selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising a therapeutically effective amount of a compound, or pharmaceutically acceptable salt thereof, having the structure of Formula I:
- wherein:
- R1 is H;
- R2 is independently selected from the group consisting of H and —(C1-9 alkyl)nN(R9)2;
- R3 is H;
- R4 is independently selected from the group consisting of -aryl(R13)q, -furyl(R15)q, and -thiophenyl(R15)q;
- R5 is H;
- each R8 is a substituent attached to the heterocyclyl ring and independently selected from the group consisting of H, halide, and —C1-4 alkyl;
- each R9 is independently selected from the group consisting of H, —C1-9 alkyl, —(C1-3 alkyl)ncarbocyclyl, and —(C1-9 alkyl)N(R16)2;
- each R13 is 1-2 substituents each attached to the aryl ring and independently selected from the group consisting of H, halide, —(C1-3 alkyl)nheterocyclyl(R8)q, —(C1-9 alkyl)nN(R9)2, and —(C1-9 alkyl)nNHSO2R18;
- each R15 is a substituent attached to the heteroaryl ring and independently selected from the group consisting of H, lower alkyl, halide, —CF3, CN, and —C(═O)(C1-3 alkyl);
- each R16 is independently selected from the group consisting of H and lower alkyl;
- each R18 is a lower alkyl;
- A is C;
- each q is independently an integer of 1 or 2;
- each n is independently an integer of 0 or 1;
- and
- a pharmaceutically acceptable excipient.
A pharmaceutical composition comprising a therapeutically effective amount of a compound having the structure of:
- pharmaceutically acceptable salt thereof;
- and
- a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.